In people with central nervous system (CNS) lymphoma, cancerous B cells—a type of white blood cell—accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels. This disease is quite ...
Feb 17, 2021
0
11
Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not responded to other systemic treatment, the U.S. Food and Drug Administration ...
Feb 9, 2021
0
0
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
A first-of-its-kind Australian study has revealed rates of brain lymphoma have quadrupled since the 1980s with only 33% of people surviving five years after receiving a diagnosis.
Feb 2, 2021
0
1
Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.
Dec 16, 2020
0
73
Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The ...
Dec 10, 2020
0
2
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller ...
Dec 10, 2020
0
84
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists ...
Dec 7, 2020
0
2
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients ...
Dec 7, 2020
0
2
A new biomarker discovered by a team that includes researchers from Penn Medicine identifies patients with an aggressive form of lymphoma unlikely to respond to the targeted treatment ibrutinib. It's a clinically actionable ...
Dec 7, 2020
0
2
